Patients’ experiences of long-acting injectable antipsychotics: a qualitative study

References

• Cheng TM. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22(3):61–76.12757273
   PubMed Web of Science ®Google Scholar
• National Health Insurance Administration, Ministry of Health and Welfare. Availble from: https://www.nhi.gov.tw/Content_List.aspx?n=5AA7CAFFF61CB16D&topn=3FC7D09599D25979. Accessed June 21, 2019.
   Google Scholar
• Getzen H, Beasley M, D’Mello DA. Barriers to utilizing long-acting injectable antipsychotic medications. Ann Clin Psychiatry. 2013;25(4):E1–E6.24199223
   PubMedGoogle Scholar
• Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. doi:10.4088/JCP.13r0844024229745
   PubMed Web of Science ®Google Scholar
• Benson CJ, Joshi K, Lapane KL, Fastenau J. Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics. Curr Med Res Opin. 2015;31(7):1437–1448. doi:10.1185/03007995.2015.105036525978698
   PubMed Web of Science ®Google Scholar
• Lin J, Wong B, Offord S, Mirski D. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res. 2013;40(3):355–366. doi:10.1007/s11414-013-9329-z23579871
   PubMed Web of Science ®Google Scholar
• Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in Context 2015;4:212267. doi: 10.7573/dic.212267
   Google Scholar
• Corigliano V, Comparelli A, Mancinelli I, et al. Long-acting injectable second-generation antipsychotics improve negative symptoms and suicidal ideation in recent diagnosed schizophrenia patients: a 1-year follow-up pilot study. Schizophr Res Treatment. 2018;4834135.30245878
   PubMed Web of Science ®Google Scholar
• Macfadden W, DeSouza C, Crivera C, et al. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry. 2011;11:167. doi:10.1186/1471-244X-11-16721999346
   PubMed Web of Science ®Google Scholar
• Pilon D, Tandon N, Lafeuille M-H, et al. Treatment patterns, health care resource utilization, and spending in medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther. 2017;39(10):1972–1985.e1972. doi:10.1016/j.clinthera.2017.08.00828919292
   PubMed Web of Science ®Google Scholar
• Liu CC, Shan JC, Chiang CL, et al. Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia–A 3-year follow-up. J Formos Med Assoc. 2015;114(6):539–545. doi:10.1016/j.jfma.2013.01.00426062967
   PubMed Web of Science ®Google Scholar
• Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211–219. doi:10.1177/009121741663660127079779
   PubMed Web of Science ®Google Scholar
• Suzuki H, Hibino H, Inoue Y, Takaya A. Comparisons of the effects of second-generation antipsychotics long-acting injections on treatment retention according to severity of patient condition. Asian J Psychiatr. 2018;37:64–66. doi:10.1016/j.ajp.2018.08.00930144778
   PubMed Web of Science ®Google Scholar
• Prikryl R, Prikrylova Kucerova H, Vrzalova M, Ceskova E. Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treatment. 2012;2012:764769. doi:10.1155/2012/76476922966444
   PubMedGoogle Scholar
• Titus-Lay EN, Ansara ED, Isaacs AN, Ott CA. Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. Ment Health Clin. 2018;8(2):56–62. doi:10.9740/mhc.2018.03.05629955546
   PubMedGoogle Scholar
• Liu C-H, Tsai P-H, Chen C-Y. Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey. Neuropsychiatr Dis Treat. 2018;14:429–433. doi:10.2147/NDT.S15449029440904
   PubMed Web of Science ®Google Scholar
• Heres S, Reichhart T, Hamann J, Mendel R, Leucht S, Kissling W. Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry. 2011;26(5):297–301. doi:10.1016/j.eurpsy.2009.12.02020570493
   PubMed Web of Science ®Google Scholar
• Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13:261. doi:10.1186/1471-244X-13-26124131801
   PubMed Web of Science ®Google Scholar
• Sutton J, Austin Z. Qualitative research: data collection, analysis, and management. Can J Hosp Pharm. 2015;68(3):226–231. doi:10.4212/cjhp.v68i3.145626157184
   PubMedGoogle Scholar
• Strauss ACJ. Basics of Qualitative Research: Grounded Theory Procedures and Techniques. Thousand Oaks, CA: Sage; 1990.
   Google Scholar
• Patel MX, de Zoysa N, Bernadt M, Bindman J, David AS. Are depot antipsychotics more coercive than tablets? The patient’s perspective. J Psychopharmacol. 2010;24(10):1483–1489. doi:10.1177/026988110910313319304865
   PubMed Web of Science ®Google Scholar
• Das AK, Malik A, Haddad PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol. 2014;4(5):179–185. doi:10.1177/204512531454209825360242
   PubMedGoogle Scholar
• Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part I-patient perspectives. Can J Psychiatry. 2013;58(5Suppl 1):14s–22s. doi:10.1177/088740341305805s0323945063
   PubMed Web of Science ®Google Scholar
• Svedberg B, Backenroth-Ohsako G, Lutzen K. On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs. 2003;12(2):110–118.12956022
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Reilly KR, Fu DJ, Alphs L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7–8):17–23.
   PubMedGoogle Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693. doi:10.1001/jamapsychiatry.2017.132228593216
   PubMed Web of Science ®Google Scholar
• Pedley R, McWilliams C, Lovell K, et al. Qualitative systematic review of barriers and facilitators to patient-involved antipsychotic prescribing. BJPsych Open. 2018;4(1):5–14. doi:10.1192/bjo.2017.529388908
   PubMed Web of Science ®Google Scholar